2024 expert consensus on clinical pathway for transcatheter aortic valve replacement in China
10.3969/j.issn.1004-8812.2024.11.001
- VernacularTitle:中国经导管主动脉瓣置换术临床路径专家共识(2024版)
- Author:
Structural Cardiology Committee of Cardiovascular Physicians Branch,Chinese Medical Doctor Association
;
Asia Pacific Structural Heart Disease Club
;
Guang-Yuan SONG
;
Wen-Zhi PAN
;
Da-Xin ZHOU
;
Yong-Jian WU
- Keywords:
Transcatheter aortic valve replacement;
Clinical evaluation;
Imaging assessment;
Standardized transcatheter aortic valve replacement procedures;
Perioperative management
- From:
Chinese Journal of Interventional Cardiology
2024;32(11):601-617
- CountryChina
- Language:Chinese
-
Abstract:
Transcatheter aortic valve replacement(TAVR)has reached maturity and has entered a stage of steady and stable development in China.From 2017 to 2023,the number of centers conducting TAVR in China has increased from less than 10 to over 600,and the annual implantation volume has increased from hundreds to over 10 000.The 2018 and 2021 editions of the"Expert Consensus on Clinical Pathway for Transcatheter Aortic Valve Replacement in China"played a crucial guiding role during the golden period of TAVR development in China.With significant progress in evidence-based practice,clinical experience,guideline updates,device development,and procedure technique improvements in the TAVR field,especially the important advances in technologies developed from China,protocol optimization based on Chinese clinical practices,it is necessary to update the previous clinical pathway consensus.The new version of the clinical pathway expert consensus has updated the standard procedures for preoperative clinical assessment,perioperative imaging evaluation,standardized procedural processes,comprehensive perioperative management,and postoperative rehabilitation follow-up for TAVR patients.This update aims to further promote the healthy and standardized development of TAVR technology in China and to steadily enhance the medical and scientific research capabilities with this therapeutic technology.
